<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12473422</article-id><article-id pub-id-type="pmcid-ver">PMC12473422.1</article-id><article-id pub-id-type="pmcaid">12473422</article-id><article-id pub-id-type="pmcaiid">12473422</article-id><article-id pub-id-type="pmid">41012435</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17091096</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-01096</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Impact of Different Drying Processes on the Physico-Chemical Properties of Liquitablet Formulations Containing Lornoxicam</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4457-5298</contrib-id><name name-style="western"><surname>Balla-Bartos</surname><given-names initials="C">Csilla</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-0402-8217</contrib-id><name name-style="western"><surname>Gamiel</surname><given-names initials="A">Alaa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Motzwickler-N&#233;meth</surname><given-names initials="A">Anett</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5496-1710</contrib-id><name name-style="western"><surname>Ambrus</surname><given-names initials="R">Rita</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="c1-pharmaceutics-17-01096" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Barresi</surname><given-names initials="AA">Antonello A.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-01096">Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, E&#246;tv&#246;s Utca 6, 6720 Szeged, Hungary; <email>bartos.csilla@szte.hu</email> (C.B.-B.); <email>gamiel.alaa@stud.u-szeged.hu</email> (A.G.); <email>nemeth.anett@szte.hu</email> (A.M.-N.)</aff><author-notes><corresp id="c1-pharmaceutics-17-01096"><label>*</label>Correspondence: <email>ambrus.rita@szte.hu</email>; Tel.: +36-62-545-572</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>17</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">497664</issue-id><elocation-id>1096</elocation-id><history><date date-type="received"><day>11</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>19</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>27</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-17-01096.pdf"/><abstract><p><bold>Background</bold>: Enhancing bioavailability is the target of most pharmaceutical research; this can be achieved by modifying the physico-chemical characteristics of poorly water-soluble drugs intended for oral administration using different techniques. The preparation of liquitablets by blister molding technique provides an opportunity to increase the bioavailability of the drug using an optimal combination of release-facilitating additives. Lornoxicam is an effective non-steroidal anti-inflammatory drug with low water solubility. This study aimed to formulate a novel lornoxicam-containing liquitablets. The effect of different drying techniques on the physico-chemical properties and in vitro dissolution of lornoxicam was investigated. The physical parameters of the tablets were also studied. <bold>Methods</bold>: The additives applied in the formulation included Tween<sup>&#174;</sup> 80, Polyvinylpyrrolidone (PVP K90), Avicel<sup>&#174;</sup> PH-102, and sodium bicarbonate. Vacuum-drying and freeze-drying were employed to produce liquitablets. The influence of various drying methods on crystallinity and intra- and interparticle phenomena was investigated. In Vitro dissolution tests were performed at pH 1.2, and a comparison was made between our products and commercial tablets using the pairwise similarity factor model (f2). <bold>Results</bold>: The liquitablets demonstrated high hydrophilicity and a lower crystallinity of the drug. Freeze-dried liquitablet showed improved dissolution compared to that of the pure drug or the vacuum-dried product. A similarity was observed between our freeze-dried product and the marketed fast-release tablets. <bold>Conclusions</bold>: This research demonstrates that preparation of liquitablet in combination with freeze-drying has a significantly positive effect in improving the in vitro dissolution rate of lornoxicam.</p></abstract><kwd-group><kwd>lornoxicam</kwd><kwd>in vitro dissolution</kwd><kwd>liquitablets</kwd><kwd>freeze-drying</kwd><kwd>vacuum-drying</kwd></kwd-group><funding-group><award-group><funding-source>University of Szeged Open Access Fund</funding-source></award-group><award-group><funding-source>Ministry of Culture and Innovation of Hungary from the National Research, Development and Innovation Fund</funding-source><award-id>Nr 8025</award-id><award-id>TKP2021-EGA-32</award-id></award-group><award-group><funding-source>TKP2021-EGA funding scheme</funding-source></award-group><funding-statement>The work was supported by University of Szeged Open Access Fund. A Grant Nr 8025 and Project no TKP2021-EGA-32 has been implemented with the support provided by the Ministry of Culture and Innovation of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-EGA funding scheme.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-01096"><title>1. Introduction</title><p>In recent years, there has been growing interest in developing new pharmaceutically active ingredients. It is worth mentioning that about 40% of approved drugs and nearly 90% of the newly developed chemical entities under development are poorly water-soluble compounds [<xref rid="B1-pharmaceutics-17-01096" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-17-01096" ref-type="bibr">2</xref>]. These insoluble drugs are associated with many problems, such as slow dissolution rate, suboptimal plasma concentration, and poor drug bioavailability [<xref rid="B3-pharmaceutics-17-01096" ref-type="bibr">3</xref>], which challenge drug development in addition to difficult and complex formulation processes [<xref rid="B4-pharmaceutics-17-01096" ref-type="bibr">4</xref>]. Several physical and chemical approaches have been used by scientists in pharmaceutical technology to overcome these problems and produce effective drug formulations, such as formation of prodrug [<xref rid="B5-pharmaceutics-17-01096" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-17-01096" ref-type="bibr">6</xref>], solubilization by cosolvency [<xref rid="B7-pharmaceutics-17-01096" ref-type="bibr">7</xref>], co-crystal and salt formation [<xref rid="B8-pharmaceutics-17-01096" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-17-01096" ref-type="bibr">9</xref>], particle size reduction (micronization and nanonization) [<xref rid="B10-pharmaceutics-17-01096" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-17-01096" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceutics-17-01096" ref-type="bibr">12</xref>], complexation [<xref rid="B13-pharmaceutics-17-01096" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-17-01096" ref-type="bibr">14</xref>], lipid-based formulation [<xref rid="B15-pharmaceutics-17-01096" ref-type="bibr">15</xref>] and amorphization using solid dispersion [<xref rid="B16-pharmaceutics-17-01096" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-17-01096" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-01096" ref-type="bibr">18</xref>]. Preparation of liquitablets, a recently developed dosage form [<xref rid="B19-pharmaceutics-17-01096" ref-type="bibr">19</xref>], is also a possibility to improve the bioavailability of the drug, which requires the use of appropriate solid and liquid liberation modulators. The increased dissolution rate of the drug can be attributed to the hydrophilic character of additives used for liquitablet preparation. In such a system, liquid vehicles can be polyethylene glycols, Propylene glycol, and Tween<sup>&#174;</sup> 85 [<xref rid="B20-pharmaceutics-17-01096" ref-type="bibr">20</xref>], the solid carrier could be microcrystalline cellulose [<xref rid="B19-pharmaceutics-17-01096" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-17-01096" ref-type="bibr">20</xref>], and sodium bicarbonate as a microenvironmental pH-modifier [<xref rid="B19-pharmaceutics-17-01096" ref-type="bibr">19</xref>]. Moreover, the employment of hydrophilic polymers such as polyvinylpyrrolidone (PVP), recognized for its binder functionality to achieve a balance between the tablet&#8217;s mechanical strength and an acceptable level of friability [<xref rid="B21-pharmaceutics-17-01096" ref-type="bibr">21</xref>]. Formulation of liquitablets can also be implemented by direct compression and blister molding technique. Blister molding process is a simple and cost-effective method for drug formulation. There is literature on the preparation of liquitablets containing different drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs): naproxen [<xref rid="B19-pharmaceutics-17-01096" ref-type="bibr">19</xref>] and ketoprofen [<xref rid="B20-pharmaceutics-17-01096" ref-type="bibr">20</xref>], hydrochlorothiazide [<xref rid="B22-pharmaceutics-17-01096" ref-type="bibr">22</xref>], etc.</p><p>Lornoxicam (LXM) is a potent oxicam NSAID with analgesic, anti-inflammatory, and antipyretic pharmacological actions [<xref rid="B23-pharmaceutics-17-01096" ref-type="bibr">23</xref>]. It shows remarkable efficacy in controlling presurgical and post-surgical pain associated with gynecological, orthopedic, abdominal, and dental procedures. It is available on the market as oral and parenteral formulations in doses of 4&#8211;8 mg and 4 mg/mL, respectively. However, its utility is restricted by its poor solubility and short half-life (3&#8211;5 h) [<xref rid="B24-pharmaceutics-17-01096" ref-type="bibr">24</xref>]. Several strategies have been studied to improve the dissolution rate and oral bioavailability, thereby reducing side effects of LXM, such as solid dispersion [<xref rid="B25-pharmaceutics-17-01096" ref-type="bibr">25</xref>], self-emulsifying system [<xref rid="B26-pharmaceutics-17-01096" ref-type="bibr">26</xref>], complexation by inclusion in &#946;-cyclodextrin [<xref rid="B27-pharmaceutics-17-01096" ref-type="bibr">27</xref>], co-crystallization [<xref rid="B28-pharmaceutics-17-01096" ref-type="bibr">28</xref>], and the use of a nanocarrier [<xref rid="B29-pharmaceutics-17-01096" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-01096" ref-type="bibr">30</xref>]. The conventional liquisolid technique has been applied to LXM, using propylene glycol or polyethylene glycol 400 as a solvent, and microcrystalline cellulose and silicon dioxide were used as additives, primarily to achieve sustained drug release [<xref rid="B31-pharmaceutics-17-01096" ref-type="bibr">31</xref>]. LXM is widely used in Europe and other global regions; however, its formulation choices are comparatively constrained when juxtaposed with other NSAIDs. The development of cost-effective, stable, and patient-centric formulations has the potential to improve accessibility and therapeutic outcomes in various markets. In our previous work, we prepared blister-packed immediate release liquitablets with enhanced dissolution rate and reduced gastric irritation in vivo. The investigation of the combination of excipients (wetting agent, binder, solubilizer, pH-modifier, carrier) was chosen to obtain the optimum composition [<xref rid="B32-pharmaceutics-17-01096" ref-type="bibr">32</xref>]. To prepare liquitablets, drying was applied at room temperature, which required a prolonged period (7&#8211;10 days).</p><p>In this study, our objective is to examine&#8211;as a preformulation study&#8211;the impact of various drying methods, specifically vacuum-drying and freeze-drying, on the physico-chemical properties and in vitro dissolution of LXM in an oral liquitablet, which was prepared without the use of organic solvents. Consequently, this preformulation study contributes to pharmaceutical research on both LXM and the blister molding technique by presenting an oral formulation of improved solubility with minimum gastric side effects.</p></sec><sec id="sec2-pharmaceutics-17-01096"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-01096"><title>2.1. Materials</title><p>The active pharmaceutical ingredient (API) was LXM (6-Chloro-4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno [2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide) (Tokyo Chemical Industry, Tokyo, Japan). Polyvinylpyrrolidone K90 (PVP K90) (Sigma-Aldrich, Shanghai, China) used as a binder, Tween<sup>&#174;</sup> 80 (Sigma-Aldrich Chemie GmbH, Darmstadt, Germany) as a wetting agent and liquid solvent, sodium bicarbonate (Sigma-Aldrich Co., Ltd., Budapest, Hungary), used as an alkanizer, and Avicel<sup>&#174;</sup> PH-102 (FMC Corporation, Philadelphia, PA, USA) as a carrier and solid matrix producer were chosen as excipients and purified water was used to prepare the aqueous solutions.</p></sec><sec id="sec2dot2-pharmaceutics-17-01096"><title>2.2. Methods</title><sec id="sec2dot2dot1-pharmaceutics-17-01096"><title>2.2.1. Solubility Studies as Preliminary Experiments</title><p>For the solubility test, different solvents and the effect of solubility regulators&#8212;chosen based on our previous experiences&#8212;were investigated. An excess amount of LXM was introduced into screw-capped bottles containing each solvent (distilled water at pH 6.8, buffer solution at pH 1.2, pure Tween<sup>&#174;</sup> 80, and a mixture of Tween<sup>&#174;</sup> 80 and a 15% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic> aqueous solution of NaHCO<sub>3</sub> in a 3:1 volume ratio). The mixtures were subjected to magnetic stirring at a temperature of 25 &#177; 5 &#176;C for a duration of 24 h. Subsequently, the samples were filtered, and the filtrate was analyzed using spectrophotometric methods (UV/vis spectrophotometry with an UV/VIS Spectrophotometer (ATI-Unicam, Cambridge, UK) at 375 nm to determine the drug concentration [<xref rid="B32-pharmaceutics-17-01096" ref-type="bibr">32</xref>].</p></sec><sec id="sec2dot2dot2-pharmaceutics-17-01096"><title>2.2.2. Sample Preparation</title><p>For the preparation of LXM liquitablets, first, the drug was dissolved in the optimized mixture of solid and liquid release modulators (<xref rid="pharmaceutics-17-01096-f001" ref-type="fig">Figure 1</xref>): Tween<sup>&#174;</sup> 80 is utilized due to its substantial ability to enhance the solubilization of drugs with poor solubility [<xref rid="B33-pharmaceutics-17-01096" ref-type="bibr">33</xref>] and its low cytotoxicity [<xref rid="B34-pharmaceutics-17-01096" ref-type="bibr">34</xref>]; PVP K90, although predominantly used as a binder [<xref rid="B35-pharmaceutics-17-01096" ref-type="bibr">35</xref>], demonstrates multifunctional characteristics, including inhibition of drug recrystallization during the dissolution process [<xref rid="B36-pharmaceutics-17-01096" ref-type="bibr">36</xref>]; and Avicel<sup>&#174;</sup> PH-102, in addition to its role as a carrier [<xref rid="B20-pharmaceutics-17-01096" ref-type="bibr">20</xref>,<xref rid="B35-pharmaceutics-17-01096" ref-type="bibr">35</xref>], is recognized for its wicking capacity, which contributes to the enhancement of dissolution [<xref rid="B37-pharmaceutics-17-01096" ref-type="bibr">37</xref>]. The composition of the prepared products is demonstrated in <xref rid="pharmaceutics-17-01096-t001" ref-type="table">Table 1</xref>. To produce a sample set consisting of 10 solid tablets per 10 mL solution, the dispersion of 80 mg LXM in 2 mL of Tween<sup>&#174;</sup> 80 was prepared using a magnetic stirrer. An aqueous solution containing PVP K90 (5% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>), which was found to yield the most effective results in maintaining tablet integrity in our previous study, and sodium bicarbonate (15% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>), which was determined to provide optimal solubility [<xref rid="B32-pharmaceutics-17-01096" ref-type="bibr">32</xref>] were prepared and subsequently incorporated into the drug and Tween<sup>&#174;</sup> 80 mixture, as a wetting agent, followed by the addition of Avicel<sup>&#174;</sup> PH-102 [<xref rid="B38-pharmaceutics-17-01096" ref-type="bibr">38</xref>]. The resultant liquid mixtures were filled into blisters and subjected to a drying process, utilizing either vacuum-drying in a Binder VDL drying oven (Binder GmbH, Tuttlingen, Germany at 25 &#176;C for 24 h or a freeze-dryer. Blister was then placed into a laboratory freeze-drying apparatus, Scanvac CoolSafe 100&#8211;9 Pro (LaboGeneApS, Lynge, Denmark), equipped with a Rotary Vane vacuum pump (Vacuubrand RZ 2.5, Wertheim, Germany). The apparatus was pre-frozen to maintain the sample trays within the drying chamber at &#8722;40 &#176;C. Process parameters were continuously monitored and recorded via the software (Scanlaf CTS16a02, version 7) at a cycle setting of &#8722;40 &#176;C and 0.2&#8211;0.5 mbar for 36 h within a vacuum oven dryer. The primary drying phase was conducted at &#8722;40 &#176;C and 0.012 mbar for 16 h, followed by a secondary drying phase at 0 &#176;C and 0.012 mbar for 2 h based on the method used by our research laboratory group. After 36 h, liquitablets were obtained.</p><p>The reference physical mixture (PM) was formulated by combining LXM with the additives (Tween<sup>&#174;</sup> 80, Polyvinylpyrrolidone (PVP K90), Avicel<sup>&#174;</sup> PH-102, and sodium bicarbonate) in proportions identical to those utilized in the formulation, at 50 rpm for 10 min employing a shaker mixer (Turbula System Schatz; Willy A. Bachofen AG Maschinenfabrik, Basel, Switzerland). It should be noted that the liquid constituent, Tween<sup>&#174;</sup> 80, was completely adsorbed by the solid carrier, Avicel<sup>&#174;</sup> PH-102, facilitating uniform assimilation and distribution throughout the mixture.</p></sec><sec id="sec2dot2dot3-pharmaceutics-17-01096"><title>2.2.3. Liquitablets Characterization</title><sec><title>Liquitablets Parameters</title><p>Three tablets of each formula were individually weighed, and the average weight and the mass difference were calculated. The width and length of the tablets were determined using a screw micrometer (Mitutoyo Corp., Tokyo, Japan).</p></sec><sec><title>Differential Scanning Calorimetry (DSC) Thermogravimetric Analysis (TGA)</title><p>The thermal properties of the products (VDLT and FDLT) were examined and compared with those of API and PM through the interpretation of the DSC and TGA patterns, utilizing the Mettler Toledo DSC 821e thermal analysis system equipped with the STARe SW 16.3 thermal analysis software version 9.0 provided by Mettler Toledo (Mettler Inc. Schwerzenbach, Switzerland). Approximately 2&#8211;5 mg of samples were hermetically sealed in flat-bottom aluminum pans and heated at a constant rate of 10 &#176;C/min in an atmosphere of nitrogen in a temperature range of 20&#8211;400 &#176;C [<xref rid="B39-pharmaceutics-17-01096" ref-type="bibr">39</xref>].</p></sec><sec><title>X-Ray Powder Diffraction Analysis (XRPD)</title><p>API, physical mixture of API-excipient (PM), vacuum-dried product (VDLT), and freeze-dried product (FDLT) were evaluated by powder X-ray diffraction analysis (XRPD) (BRUKER D8 Advance Diffractometer, Bruker AXS GmbH, Karlsruhe, Germany) to evaluate solid-state physical structure. Approximately 10 mg of the sample material was finely ground prior to deposition in the holder. The experimental parameters were established as follows: Cu K&#955;1 radiation (&#955; = 1.5406 &#197;) constituted the radiation source, and the samples were scanned at temperatures of 40 kV and 40 mA in an angular range of 3&#8211;40&#176; 2-Theta (2&#952;). A temporal resolution of 0.1 s per step was employed with an increase in step of 0.01&#176;, and the calibration of the X-ray instrument was performed using standard aluminum oxide powder. The crystallinity index (<italic toggle="yes">Xc</italic>%) for each sample was quantitatively ascertained utilizing Equation (1) via the DIFFRAC.EVA.V5.2 software and data from the Cambridge Structural Database were used as a reference.</p><p><disp-formula id="FD1-pharmaceutics-17-01096"><label>(1)</label><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>X</mml:mi><mml:mi>c</mml:mi><mml:mo>%</mml:mo><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>r</mml:mi><mml:mi>y</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mo>&#160;</mml:mo><mml:mo>&#160;</mml:mo><mml:mo>&#160;</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
where</p><p><italic toggle="yes">Xc</italic>% is the crystallinity index,</p><p><italic toggle="yes">A<sub>crystalline</sub></italic> refers to the area under the crystalline peaks, and</p><p><italic toggle="yes">A<sub>total</sub></italic> indicates the total area of the diffractogram.</p></sec><sec><title>Fourier Transform Infrared Spectroscopy (FT-IR)</title><p>The spectra of the products (VD and FDLT) were obtained and compared to the observed peaks of the API and PM spectra using Fourier transform infrared spectroscopy (AVATAR 330 FT-IR; Thermo Nicolet, Unicam Hungary Ltd., Budapest, Hungary). The samples were ground with 0.15 g of potassium bromide and compressed into a disc with 10-ton pressure. The scan was performed in the range of 4000 to 400 cm<sup>&#8722;1</sup> and with a resolution of 4 cm<sup>&#8722;1</sup>. The rsecorded bands are identified for the functional group.</p></sec><sec><title>Wettability</title><p>The surface free energy and polarity of the Active Pharmaceutical Ingredient (API) and the products (VD and FDLT) were calculated. Approximately 0.10 g of the samples were subjected to compression using a 1-ton hydraulic press (Perkin Elmer hydraulic press, Specac Inc., Waltham, MA, USA). Six pastilles were obtained from each sample. Subsequently, the surface of the pastilles was treated with polar solvents (4.8 &#181;L of purified water) and non-polar solvents (2.0 &#181;L of diiodomethane). The contact angle was measured using the Dataphysics OCA 20 apparatus (Dataphysics Inc. GmbH, Filderstadt, Germany) over an interval of 1 to 25 s. The contact angles for the two fluids were obtained successfully. The surface free energy (<italic toggle="yes">&#947;s</italic>) of the products, comprising the polar component (<italic toggle="yes">&#947;sp</italic>) and the dispersive component (<italic toggle="yes">&#947;sd</italic>); (<italic toggle="yes">&#947;s</italic> = <italic toggle="yes">&#947;sp</italic> + <italic toggle="yes">&#947;sd</italic>), was determined based on the application of the Wu equation. The surface tension values for the employed liquids can be referenced in the literature: distilled water <italic toggle="yes">&#947;p</italic> = 50.2 mN/m, <italic toggle="yes">&#947;d</italic> = 22.6 mN/m and diiodomethane <italic toggle="yes">&#947;p</italic> = 1.8 mN/m, <italic toggle="yes">&#947;d</italic> = 49 mN/m. The Wu equation (Equation (2) is illustrated below, where &#952; denotes the contact angle, <italic toggle="yes">&#947;</italic> represents the surface free energy, <italic toggle="yes">s</italic> signifies the solid phase, <italic toggle="yes">l</italic> denotes the liquid phase, d denotes the dispersion component, and <italic toggle="yes">p</italic> represents the polar component.<disp-formula id="FD2-pharmaceutics-17-01096"><label>(2)</label><mml:math id="mm2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mrow><mml:mi>cos</mml:mi><mml:mi mathvariant="normal">&#952;</mml:mi></mml:mrow></mml:mrow></mml:mfenced><mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mo>&#160;</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mrow><mml:mn>4</mml:mn><mml:mo>(</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow><mml:mi>d</mml:mi></mml:msup><mml:msup><mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mi>l</mml:mi></mml:msub></mml:mrow><mml:mi>d</mml:mi></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mi>l</mml:mi></mml:msub></mml:mrow><mml:mi>d</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>+</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mrow><mml:mn>4</mml:mn><mml:mo>(</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow><mml:mi>p</mml:mi></mml:msup><mml:msup><mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mi>l</mml:mi></mml:msub></mml:mrow><mml:mi>p</mml:mi></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:msub><mml:mi>&#947;</mml:mi><mml:mi>l</mml:mi></mml:msub></mml:mrow><mml:mi>p</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>The polarity (Pol) was calculated as the ratio between the surface free energy of the polar component and the surface free energy multiplied by 100 (Equation (3)).<disp-formula id="FD3-pharmaceutics-17-01096"><label>(3)</label><mml:math id="mm3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mrow><mml:mi>Pol</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msup><mml:mi>&#947;</mml:mi><mml:mi>p</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>&#947;</mml:mi><mml:mi>s</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mstyle><mml:mrow><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec></sec><sec id="sec2dot2dot4-pharmaceutics-17-01096"><title>2.2.4. In Vitro Dissolution Test</title><p>The dissolution test was carried out using the USP dissolution apparatus I (instrument) at 50 rpm. Weight equivalent to the dose (8 mg) was placed in the dissolution vessel containing 100 mL of simulated gastric medium (pH 1.2), maintained at 37 &#177; 0.5 &#176;C. Aliquots from the dissolution medium were withdrawn at specific time points (5, 10, 15, 30, and 60 min), and the withdrawn samples were replaced with equal volumes of fresh medium to keep the dissolution volume constant throughout the experiment. The samples were filtered through a 0.45 &#181;m Millipore filter (Millex-HV filter unit, Millipore Corporation, Bedford, MS, USA) and analyzed using a UV spectrophotometer at the predetermined &#955;max (374 nm) using a buffer of pH 1.2 as a blank. Each test was performed in triplicate, and average values and standard deviations were recorded. The drug concentration values were corrected for progressive dilution to obtain the cumulative amount dissolved using Equations (4) and (5) derived from the Wagner model for dissolution rate calculation [<xref rid="B40-pharmaceutics-17-01096" ref-type="bibr">40</xref>]:<disp-formula id="FD4-pharmaceutics-17-01096"><label>(4)</label><mml:math id="mm4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#8242;</mml:mo></mml:mrow></mml:msup><mml:mi>t</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mi>V</mml:mi><mml:mi>r</mml:mi><mml:mo>&#215;</mml:mo><mml:mi>C</mml:mi><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mi>V</mml:mi><mml:mi>s</mml:mi><mml:mo>&#215;</mml:mo><mml:mi>&#931;</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>C</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="FD5-pharmaceutics-17-01096"><label>(5)</label><mml:math id="mm5" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>&#160;</mml:mo><mml:mo>%</mml:mo><mml:mo>&#160;</mml:mo><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mo>&#8242;</mml:mo></mml:mrow></mml:msup><mml:mi>t</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:mfenced><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula>
where <italic toggle="yes">Q&#8242;t (n)</italic> is the current cumulative mass of the drug dissolved at time t.</p><p><italic toggle="yes">Cn</italic> represents the current concentration in the dissolution medium.</p><p><italic toggle="yes">&#931; Cm</italic> denotes the total sum of the previous measured concentration.</p><p><italic toggle="yes">Vr</italic> is the volume of the dissolution medium and</p><p><italic toggle="yes">Vs</italic> corresponds to the volume of the sample removed for analysis.</p><p>The dissolution data obtained were plotted as the cumulative percentage of the drug dissolved as a function of time. The dissolution profiles of the API, PM and products (VD and FDLT) were compared through the calculation of the model-independent similarity factor (<italic toggle="yes">f<sub>2</sub></italic>), which can be defined by Equation (6) [<xref rid="B41-pharmaceutics-17-01096" ref-type="bibr">41</xref>]:<disp-formula id="FD6-pharmaceutics-17-01096"><label>(6)</label><mml:math id="mm6" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>50</mml:mn><mml:mo>&#215;</mml:mo><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:msup><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mfenced close="" separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac bevelled="true"><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mfenced><mml:mrow><mml:munderover><mml:mo stretchy="false">&#8721;</mml:mo><mml:mrow><mml:mi mathvariant="normal">j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mfenced open="|" close="|" separators="|"><mml:mrow><mml:mi>R</mml:mi><mml:mi>j</mml:mi><mml:mo>&#160;</mml:mo><mml:mo>&#8722;</mml:mo><mml:mi>T</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:msup><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Furthermore, the freeze-dried liquitablets were compared to the marketed product (simple formulation (SM) and rapid formulation (RM)).</p></sec><sec id="sec2dot2dot5-pharmaceutics-17-01096"><title>2.2.5. Statistical Analysis</title><p>Statistical analyses were conducted using the GraphPad Prism 5.0.1 software (GraphPad Software, San Diego, CA, USA). A two-tailed <italic toggle="yes">t</italic>-test with measurements carried out in triplicate was performed for comparing crystallinity, and analysis of variance (ANOVA) for dissolution rate tests, in which the <italic toggle="yes">p</italic>-values &lt; 0.05 denoted statistically significant differences.</p></sec></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-01096"><title>3. Results and Discussion</title><sec id="sec3dot1-pharmaceutics-17-01096"><title>3.1. Solubility Studies</title><p>The saturated solubility of LXM in distilled water, pH 1.2, and in the presence of different excipients is shown in <xref rid="pharmaceutics-17-01096-t002" ref-type="table">Table 2</xref>. It is evident that LXM has poor solubility in pH 1.2 (0.003 mg/mL); this is due to the acidic nature of LXM, which renders it unionized at low pH. In addition, the crystalline structure could reduce the affinity of hydrogen bond formation with water, making it insoluble. Furthermore, LXM exhibits slight lipophilicity, demonstrated by an apparent partition coefficient of 1.8 in an n-octanol/buffer system at pH 7.4 and having a pKa of 4.7. Due to keto-enol tautomerism, where the presence of a basic pyrimido group with a pKa of 5.5 enhances the acidity of the enolic group to a pKa between 1 and 2, LXM becomes amphoteric, existing as a zwitterion within the physiological pH range of 2&#8211;5, and transitions to an anionic form at pH values of 6 and higher [<xref rid="B42-pharmaceutics-17-01096" ref-type="bibr">42</xref>]. The application of Tween<sup>&#174;</sup> 80&#8212;pH 6. 7&#8212;also improves solubility by forming micelles and facilitating the dissolution process; therefore, the solubility of LXM in Tween<sup>&#174;</sup> 80 increased to 6.197 mg/mL. The application of an aqueous solution of alkalizing sodium bicarbonate (15% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) demonstrated solubility enhancement as well (5.794 mg/mL). Consequently, both Tween<sup>&#174;</sup> 80 and sodium bicarbonate were incorporated into the formulation. The combination of these two solubility enhancer additives resulted in the highest solubility value of LXM: 16.56 mg/mL.</p></sec><sec id="sec3dot2-pharmaceutics-17-01096"><title>3.2. Liquitablets Parameters</title><p>All liquitablets showed physical integrity, showing no signs of damage or fragmentation during handling. Each liquitablet was successfully and completely removed from the blister packaging without adhesion. The mean percentage of LXM content, liquitablet dimensions, and average weights are shown in <xref rid="pharmaceutics-17-01096-t003" ref-type="table">Table 3</xref>. All liquitablets adhered to the pharmacopeial requirements of the average weight (weight variation range of &#177;5%), which was approximately 0.306 g in both cases [<xref rid="B43-pharmaceutics-17-01096" ref-type="bibr">43</xref>]. The drug content was above 95% for both products. The liquitablets were about 23 mm long and 9 mm wide.</p></sec><sec id="sec3dot3-pharmaceutics-17-01096"><title>3.3. Solid Phase Characterization</title><sec id="sec3dot3dot1-pharmaceutics-17-01096"><title>3.3.1. Thermoanalytical Results</title><p>DSC was employed to investigate the thermal behaviors of LXM in the raw form, in the physical mixture, and in the products prepared with different drying processes.</p><p>Combining DSC and TGA will provide a prediction of the effect of processing on drug stability [<xref rid="B44-pharmaceutics-17-01096" ref-type="bibr">44</xref>]. DSC curve of LXM did not exhibit any endothermic melting peak; nevertheless, thermal decomposition transpired concurrently, as indicated by a sharp exothermic peak occurring at 225.48 &#176;C, which is further corroborated by the TGA. Our thermal findings of LXM aligned entirely with previously published reports [<xref rid="B45-pharmaceutics-17-01096" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-17-01096" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceutics-17-01096" ref-type="bibr">47</xref>]. In the case of a physical mixture and vacuum-dried product, the thermal decomposition of LXM occurred at a lower temperature compared to that of the pure drug, which is also supported by the weight loss on the TGA curve at the same temperature. In the prepared products, DSC analysis identified a glass transition temperature (Tg) with a midpoint (ISO) of 112.35 &#176;C, and a range extending from 108.26 &#176;C to 116.41 &#176;C. The limited transition range (&#916;Tg = 8.15 &#176;C) implies the presence of an amorphous phase. TGA decomposition of the freeze-dried tablet is slowly indicating more stability than the vacuum-dried powder, which can be explained by the low moisture content (usually &#8804; 1%) of the freeze-dried product (<xref rid="pharmaceutics-17-01096-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B48-pharmaceutics-17-01096" ref-type="bibr">48</xref>].</p></sec><sec id="sec3dot3dot2-pharmaceutics-17-01096"><title>3.3.2. Structural Characterization: X-Ray Powder Diffraction Analysis (XRPD)</title><p>The crystallinity of API and products after processing was assessed using XRPD patterns (<xref rid="pharmaceutics-17-01096-f003" ref-type="fig">Figure 3</xref>). The XRPD pattern of LXM clearly exhibits sharp multiple diffraction lines at (2&#952;) angles of 8.77&#176;, 13.48&#176;, 14.33&#176;, 15.08&#176;, 18.91&#176;, 20.52&#176;, 21.53&#176;, 22.96&#176;, 24.68&#176;, 25.43&#176;, 28.05&#176;, 30.50&#176;, and 44.64&#176;, which are indicative of the crystalline characteristics of LXM [<xref rid="B49-pharmaceutics-17-01096" ref-type="bibr">49</xref>]. Notwithstanding the crystalline predominance of the API utilized in this study, it is plausible that a minor fraction of amorphous material is present. This could be attributed to the intrinsic properties of the material, conditions of synthesis, or subtle processing influences preceding the analytical evaluation, such as milling or storage. Conversely, a reduction in the intensities of diffraction lines within the sample diffractograms suggests a diminishment in the crystallinity of the drugs [<xref rid="B50-pharmaceutics-17-01096" ref-type="bibr">50</xref>], and a computed <italic toggle="yes">p</italic>-value = 0.0001 demonstrates statistical significance at the 95% confidence level. <xref rid="pharmaceutics-17-01096-t004" ref-type="table">Table 4</xref> shows the crystallinity percentage. The crystallinity of LXM in the physical mixture decreased compared with the raw drug, which can be explained by the presence of the PVP K90, which is an amorphous polymer [<xref rid="B51-pharmaceutics-17-01096" ref-type="bibr">51</xref>]. In the case of the freeze-dried product, only approximately 50% of the drug was crystalline. This phenomenon can be explained by the conditions of freeze-drying (fast freezing, vacuum sublimation), which prevent the formation of crystalline structure, and also by the PVP, which can help prevent the drug from crystallizing, maintaining it in a more soluble amorphous state [<xref rid="B52-pharmaceutics-17-01096" ref-type="bibr">52</xref>]. Crystalline drugs are generally characterized by reduced solubility attributable to the robust intermolecular forces that must be surmounted during dissolution, as evidenced by their highly packed lattice configurations. Conversely, amorphous drugs demonstrate superior solubility due to their elevated free energy and a disordered molecular arrangement, thereby accelerating dissolution rates [<xref rid="B53-pharmaceutics-17-01096" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceutics-17-01096" ref-type="bibr">54</xref>,<xref rid="B55-pharmaceutics-17-01096" ref-type="bibr">55</xref>].</p></sec><sec id="sec3dot3dot3-pharmaceutics-17-01096"><title>3.3.3. Structural Characterization: FT-IR</title><p>FT-IR spectroscopy was employed to investigate potential interactions between the LXM and the excipients used in the preformulations. The pure LXM FT-IR spectrum (<xref rid="pharmaceutics-17-01096-f004" ref-type="fig">Figure 4</xref>) showed weak and sharp absorption bands in the 3005.6&#8211;3133.0 cm<sup>&#8722;1</sup> region, corresponding to aromatic H stretch vibrations. Additional bands were observed at 1645.8 and 1594.3 with 1503.3 cm<sup>&#8722;1</sup>, attributed to the stretching vibration of the carbonyl group in the primary amide and to the bending of the N&#8211;H in the secondary amide, respectively. Stretching vibrations of the sulfonyl group were detected at 1185.4 and 1382.4 cm<sup>&#8722;1</sup> bands with weak intensities in the 690&#8211;870 cm<sup>&#8722;1</sup> range were mostly related to aromatic C&#8211;H vibrations, of which the band at 789.7 cm<sup>&#8722;1</sup> indicated the presence of C&#8211;Cl stretching [<xref rid="B56-pharmaceutics-17-01096" ref-type="bibr">56</xref>,<xref rid="B57-pharmaceutics-17-01096" ref-type="bibr">57</xref>]. These characteristic bands were partially present in the PM, especially within the fingerprint region, which confirmed the presence of the LXM. The spectrum of PM appeared as a superposition of the raw materials with no shifts in band positions, suggesting the absence of any chemical interaction between LXM and the excipients. Furthermore, the FT-IR spectra of the dried preformulations were identical to those of the PM, indicating that no new intermolecular interactions occurred during the VDLT or FD processes. Additionally, no spectral changes were observed that would suggest decomposition or structural changes at the molecular level in any of the samples.</p></sec><sec id="sec3dot3dot4-pharmaceutics-17-01096"><title>3.3.4. Wettability Investigations</title><p>Contact angle analysis was performed to determine the polarity of the materials. <xref rid="pharmaceutics-17-01096-t005" ref-type="table">Table 5</xref> presents the calculated polarity and surface free energy derived from contact angle measurements of LXM and the products. The correlation among contact angle, surface free energy, and hydrophilicity has been documented in several studies [<xref rid="B58-pharmaceutics-17-01096" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceutics-17-01096" ref-type="bibr">59</xref>]. Our results showed that the dried products had decreased contact angle values with water (&#952; water) (for VDLT: 28.76&#176;, and for FDLT: 33.60&#176;), indicating a more hydrophilic character compared to the hydrophobic raw drug (42.0&#176;). Additives (PVP K90, Tween<sup>&#174;</sup> 80, sodium bicarbonate, and Avicel<sup>&#174;</sup> PH-102), applied for the formulation of blister-molded liquitablets, were hydrophilic materials, increasing the wettability. The polarity of the products, calculated as the ratio of surface free energy of the polar component and the surface free energy, also increased, implying enhanced dissolution outcomes.</p></sec></sec><sec id="sec3dot4-pharmaceutics-17-01096"><title>3.4. Evaluation of In Vitro Dissolution Test</title><p>Dissolution profiles of API, prepared formulations, and marketed products in the simulated gastric medium (pH 1.2) are illustrated in <xref rid="pharmaceutics-17-01096-f005" ref-type="fig">Figure 5</xref>. Our liquitablets showed complete dissolution of LXM in less than 15 min compared to &lt;10% dissolution of pure drug. This improvement in dissolution rate and dissolved amount could be attributed to the effect of Tween<sup>&#174;</sup> 80, PVP K90, and the creation of a basic micro-environment with the sodium bicarbonate solution. Tween<sup>&#174;</sup> 80 and PVP, as non-ionic stabilizers with amphiphilic groups, provided steric stabilization dominated by the wetting effect [<xref rid="B60-pharmaceutics-17-01096" ref-type="bibr">60</xref>]. Furthermore, PVP kept LXM in an amorphous form. The alkaline medium, provided by sodium bicarbonate, promoted the dissolution of the acidic drug as a result of partial ionization of LXM [<xref rid="B61-pharmaceutics-17-01096" ref-type="bibr">61</xref>]. Additionally, there is a significant positive correlation between this observation and the formulation technique we used. Both drying techniques have positive effect on dissolution; however, freeze-drying has better results regarding time as the difference (&#916;) is seen at 5 min (&#916; = 18.62%) and 10 min (&#916; = 12.01%), this fits well with Taldaev et al. in their review [<xref rid="B62-pharmaceutics-17-01096" ref-type="bibr">62</xref>] and could be attributed to the amorphous structure of the LXM.</p><p>Our freeze-dried liquitablets were compared with simple (SM)- and rapid-marketed (RM) tablets containing LXM, as well. The dissolution of the SM product was slow, and only about 20% of LXM was liberated in the gastric fluid in the first 60 min. The dissolution of the freeze-dried product was like the RM tablet; over 80% of the active ingredient was released in the first 5 min and 100% within 10 min in both cases. This result was also supported by the similarity factor (<italic toggle="yes">f<sub>2</sub></italic>), calculated by the statistical pairwise model (<xref rid="pharmaceutics-17-01096-t006" ref-type="table">Table 6</xref>). The analysis of variance revealed a <italic toggle="yes">p</italic>-value of 0.0082, indicating a statistically significant difference. In order to consider similar dissolution profiles, <italic toggle="yes">f<sub>2</sub></italic> values should be higher than 50 (50&#8211;100) [<xref rid="B63-pharmaceutics-17-01096" ref-type="bibr">63</xref>]. Since <italic toggle="yes">f<sub>2</sub></italic> was found to be 79.35 for the FDLT in comparison with the RM tablet, it can be stated that the release was similar to the RM formulation.</p><p>Several studies have linked decreased crystallinity and increased wettability to enhanced dissolution. For example, Jadhav and Yadav demonstrated that the enhancement of the drug&#8217;s surface wettability through solid dispersion and reducing drug crystallinity leads to a concomitant increase in solubility and bioavailability [<xref rid="B55-pharmaceutics-17-01096" ref-type="bibr">55</xref>]. These findings are consistent with those reported by Rajebahadur et al., who demonstrated that the enhancement of solubility may arise from a partial transformation of the crystalline drug into the amorphous state, increase in the wettability of the drug by water-soluble polymers, improved separation of drug particles, micellar solubilization of the drug facilitated by elevated concentrations of surfactant polymers, and interaction between polymer and drug at the molecular level [<xref rid="B64-pharmaceutics-17-01096" ref-type="bibr">64</xref>].</p><p>The current study is limited by the lack of in vivo investigations designed to assess gastric irritation reduction in animal models, which was examined in a preceding study that serves as the basis for this work. Furthermore, the absence of a long-term stability study of this formulation constrains the conclusions about shelf-life. Future research efforts will focus on performing in vivo studies to verify the reduction in gastric irritation, along with stability testing to ascertain the formulation&#8217;s appropriateness for clinical application.</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceutics-17-01096"><title>4. Conclusions</title><p>In our work, liquitablets were prepared by applying two different drying methods. The effects of vacuum-drying and freeze-drying processes on the characteristics of blister-molded tablets were investigated. The size and weight of the liquitablets were examined. As a model drug, LXM, a poorly water-soluble NSAID, was used, and its solubility test was first carried out in different media. The effect of drying techniques on the physico-chemical properties of the products was determined. The results of the dissolution tests were compared and evaluated. Our study provides further evidence that the solubility of LXM could be successfully improved in acidic media by applying the appropriate additives. An important implication is that freeze-drying resulted in a product with high wettability (&#952; water = 33.60&#176;) and the decreased crystallinity of the drug (&#8776;50%). No chemical interaction between LXM and the excipients, and no new intermolecular interactions were detected during the drying procedures. Preparation of liquitablets with both drying methods had a prominent effect on the dissolution rate (100% in the first 15 min) compared with the pure drug and physical mixture. Freeze-dried product showed a similar dissolution curve as the rapid-marketed product (<italic toggle="yes">f<sub>2</sub></italic> = 66).</p><p>Together, the formulation of liquitablets using the blister molding technique may provide a solution to the challenges of poorly water-soluble active ingredients. Because water is used as a dispersion medium, the procedure is considered a green technology, while the product is organic solvent-free. The findings of our research suggest the possibility of a supergeneric formulation as an advanced oral dosage form of LXM with rapid dissolution. A combination of solid and liquid additives makes the usage of much fewer excipients possible than those found in the marketed products.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by the NKFIH OTKA K_146148 project.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, C.B.-B. and R.A.; methodology, C.B.-B. and R.A.; software, A.G.; formal analysis, A.G., C.B.-B., and R.A.; investigation, A.G., C.B.-B., A.M.-N., and R.A.; resources, R.A.; data curation, A.G., C.B.-B., and R.A.; writing&#8212;original draft preparation A.G. and C.B.-B.; writing&#8212;review and editing, C.B.-B., R.A., and A.M.-N.; visualization, A.G.; supervision, C.B.-B. and R.A.; project administration: R.A.; funding acquisition, R.A. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in the study are included in the article; further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">API</td><td align="left" valign="middle" rowspan="1" colspan="1">active pharmaceutical ingredient</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LXM</td><td align="left" valign="middle" rowspan="1" colspan="1">lornoxicam</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PVP K90</td><td align="left" valign="middle" rowspan="1" colspan="1">polyvinylpyrrolidone K90 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PM</td><td align="left" valign="middle" rowspan="1" colspan="1">physical mixture</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VDLT</td><td align="left" valign="middle" rowspan="1" colspan="1">vacuum-dried liquitablets</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FDLT</td><td align="left" valign="middle" rowspan="1" colspan="1">freeze-dried liquitablets</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">w</italic>/<italic toggle="yes">w</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">weight per weight</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DSC</td><td align="left" valign="middle" rowspan="1" colspan="1">differential scanning calorimetry</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGA</td><td align="left" valign="middle" rowspan="1" colspan="1">thermogravimetric Analysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tg</td><td align="left" valign="middle" rowspan="1" colspan="1">glass transition</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">XRPD</td><td align="left" valign="middle" rowspan="1" colspan="1">X-ray powder diffraction analysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FT-IR</td><td align="left" valign="middle" rowspan="1" colspan="1">Fourier transform infrared spectroscopy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">min</td><td align="left" valign="middle" rowspan="1" colspan="1">minute</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">mm</td><td align="left" valign="middle" rowspan="1" colspan="1">millimeter</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SM</td><td align="left" valign="middle" rowspan="1" colspan="1">simple marketed</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RM</td><td align="left" valign="middle" rowspan="1" colspan="1">rapid marketed</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-pharmaceutics-17-01096"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalepu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nekkanti</surname><given-names>V.</given-names></name></person-group><article-title>Insoluble drug delivery strategies: Review of recent advances and business prospects</article-title><source>Acta Pharm. Sin. B</source><year>2015</year><volume>5</volume><fpage>442</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2015.07.003</pub-id><pub-id pub-id-type="pmid">26579474</pub-id><pub-id pub-id-type="pmcid">PMC4629443</pub-id></element-citation></ref><ref id="B2-pharmaceutics-17-01096"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gowthami</surname><given-names>B.</given-names></name><name name-style="western"><surname>Krishna</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>D.S.</given-names></name></person-group><article-title>Novel approaches to enhance oral bioavailability of poorly soluble drugs</article-title><source>Int. J. Res. Pharm. Sci.</source><year>2020</year><volume>2</volume><fpage>12</fpage><lpage>16</lpage></element-citation></ref><ref id="B3-pharmaceutics-17-01096"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nyamba</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sombi&#233;</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Yabr&#233;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zim&#233;-Diawara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yam&#233;ogo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ou&#233;draogo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lechanteur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Semd&#233;</surname><given-names>R.</given-names></name><name name-style="western"><surname>Evrard</surname><given-names>B.</given-names></name></person-group><article-title>Pharmaceutical approaches for enhancing solubility and oral bioavailability of poorly soluble drugs</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2024</year><volume>204</volume><elocation-id>114513</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejpb.2024.114513</pub-id><pub-id pub-id-type="pmid">39313163</pub-id></element-citation></ref><ref id="B4-pharmaceutics-17-01096"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumari</surname><given-names>L.</given-names></name><name name-style="western"><surname>Choudhari</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Das Gupta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rosenholm</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Das Kurmi</surname><given-names>B.</given-names></name></person-group><article-title>Advancement in Solubilization Approaches: A Step towards Bioavailability Enhancement of Poorly Soluble Drugs</article-title><source>Life</source><year>2023</year><volume>13</volume><elocation-id>1099</elocation-id><pub-id pub-id-type="doi">10.3390/life13051099</pub-id><pub-id pub-id-type="pmid">37240744</pub-id><pub-id pub-id-type="pmcid">PMC10221903</pub-id></element-citation></ref><ref id="B5-pharmaceutics-17-01096"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karbasi</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Barfuss</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>D.</given-names></name><name name-style="western"><surname>Costenbader</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Dennis</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Hinman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>K.</given-names></name><name name-style="western"><surname>Messina</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>K.C.</given-names></name><etal/></person-group><article-title>Sol-moiety: Discovery of a water-soluble prodrug technology for enhanced oral bioavailability of insoluble therapeutics</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>8487</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-52793-6</pub-id><pub-id pub-id-type="pmid">39353935</pub-id><pub-id pub-id-type="pmcid">PMC11445516</pub-id></element-citation></ref><ref id="B6-pharmaceutics-17-01096"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stella</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Nti-Addae</surname><given-names>K.W.</given-names></name></person-group><article-title>Prodrug strategies to overcome poor water solubility</article-title><source>Adv. Drug Deliv. Rev.</source><year>2007</year><volume>59</volume><fpage>677</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2007.05.013</pub-id><pub-id pub-id-type="pmid">17628203</pub-id></element-citation></ref><ref id="B7-pharmaceutics-17-01096"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Millard</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Alvarez-N&#250;&#241;ez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yalkowsky</surname><given-names>S.H.</given-names></name></person-group><article-title>Solubilization by Cosolvents: Establishing Useful Constants for the Log-Linear Model</article-title><source>Int. J. Pharm.</source><year>2002</year><volume>245</volume><fpage>153</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/S0378-5173(02)00334-4</pub-id><pub-id pub-id-type="pmid">12270252</pub-id></element-citation></ref><ref id="B8-pharmaceutics-17-01096"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chettri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Subba</surname><given-names>A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Bag</surname><given-names>P.P.</given-names></name></person-group><article-title>Pharmaceutical co-crystals: A green way to enhance drug stability and solubility for improved therapeutic efficacy</article-title><source>J. Pharm. Pharmacol.</source><year>2024</year><volume>76</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1093/jpp/rgad097</pub-id><pub-id pub-id-type="pmid">37934904</pub-id></element-citation></ref><ref id="B9-pharmaceutics-17-01096"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blagden</surname><given-names>N.</given-names></name><name name-style="western"><surname>De Matas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gavan</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>York</surname><given-names>P.</given-names></name></person-group><article-title>Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates</article-title><source>Adv. Drug Deliv. Rev.</source><year>2007</year><volume>59</volume><fpage>617</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2007.05.011</pub-id><pub-id pub-id-type="pmid">17597252</pub-id></element-citation></ref><ref id="B10-pharmaceutics-17-01096"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ambrus</surname><given-names>R.</given-names></name><name name-style="western"><surname>Alshweiat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Szab&#243;-R&#233;v&#233;sz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bartos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cs&#243;ka</surname><given-names>I.</given-names></name></person-group><article-title>Smartcrystals for Efficient Dissolution of Poorly Water-Soluble Meloxicam</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>245</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14020245</pub-id><pub-id pub-id-type="pmid">35213978</pub-id><pub-id pub-id-type="pmcid">PMC8879336</pub-id></element-citation></ref><ref id="B11-pharmaceutics-17-01096"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Csics&#225;k</surname><given-names>D.</given-names></name><name name-style="western"><surname>Szoll&#225;th</surname><given-names>R.</given-names></name><name name-style="western"><surname>K&#225;d&#225;r</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ambrus</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bartos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Balogh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Antal</surname><given-names>I.</given-names></name><name name-style="western"><surname>K&#246;teles</surname><given-names>I.</given-names></name><name name-style="western"><surname>T&#337;zs&#233;r</surname><given-names>P.</given-names></name><name name-style="western"><surname>B&#225;rdos</surname><given-names>V.</given-names></name><etal/></person-group><article-title>The Effect of the Particle Size Reduction on the Biorelevant Solubility and Dissolution of Poorly Soluble Drugs with Different Acid-Base Character</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>278</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15010278</pub-id><pub-id pub-id-type="pmid">36678907</pub-id><pub-id pub-id-type="pmcid">PMC9865396</pub-id></element-citation></ref><ref id="B12-pharmaceutics-17-01096"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jinno</surname><given-names>J.-I.</given-names></name><name name-style="western"><surname>Kamada</surname><given-names>N.</given-names></name><name name-style="western"><surname>Miyake</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mukai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Odomi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liversidge</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Higaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>T.</given-names></name></person-group><article-title>Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs</article-title><source>J. Control. Release</source><year>2006</year><volume>111</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2005.11.013</pub-id><pub-id pub-id-type="pmid">16410029</pub-id></element-citation></ref><ref id="B13-pharmaceutics-17-01096"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hermenean</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dossi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trotta</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lepre</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Sajtos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ruszny&#225;k</surname><given-names>&#193;.</given-names></name><name name-style="western"><surname>V&#225;radi</surname><given-names>J.</given-names></name><name name-style="western"><surname>B&#225;cskay</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Chrysin Directing an Enhanced Solubility through the Formation of a Supramolecular Cyclodextrin&#8211;Calixarene Drug Delivery System: A Potential Strategy in Antifibrotic Diabetes Therapeutics</article-title><source>Pharmaceuticals</source><year>2024</year><volume>17</volume><elocation-id>107</elocation-id><pub-id pub-id-type="doi">10.3390/ph17010107</pub-id><pub-id pub-id-type="pmid">38256940</pub-id><pub-id pub-id-type="pmcid">PMC10819853</pub-id></element-citation></ref><ref id="B14-pharmaceutics-17-01096"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>U.</given-names></name></person-group><article-title>Application of dendrimer&#8211;drug complexation in the enhancement of drug solubility and bioavailability</article-title><source>Expert Opin. Drug Metab. Toxicol.</source><year>2008</year><volume>4</volume><fpage>1035</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1517/17425255.4.8.1035</pub-id><pub-id pub-id-type="pmid">18680439</pub-id></element-citation></ref><ref id="B15-pharmaceutics-17-01096"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Holm</surname><given-names>R.</given-names></name><name name-style="western"><surname>M&#252;llertz</surname><given-names>A.</given-names></name></person-group><article-title>Lipid-based formulations for oral administration of poorly water-soluble drugs</article-title><source>Int. J. Pharm.</source><year>2013</year><volume>453</volume><fpage>215</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.03.054</pub-id><pub-id pub-id-type="pmid">23578826</pub-id></element-citation></ref><ref id="B16-pharmaceutics-17-01096"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butreddy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bandari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Repka</surname><given-names>M.A.</given-names></name></person-group><article-title>Quality-by-design in hot melt extrusion based amorphous solid dispersions: An industrial perspective on product development</article-title><source>Eur. J. Pharm. Sci.</source><year>2021</year><volume>158</volume><fpage>105655</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2020.105655</pub-id><pub-id pub-id-type="pmid">33253883</pub-id><pub-id pub-id-type="pmcid">PMC7855693</pub-id></element-citation></ref><ref id="B17-pharmaceutics-17-01096"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sripetthong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nalinbenjapun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Basit</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ovatlarnporn</surname><given-names>C.</given-names></name></person-group><article-title>Synthesis of Quarternized Chitosans and Their Potential Applications in the Solubility Enhancement of Indomethacin by Solid Dispersion</article-title><source>AAPS PharmSciTech</source><year>2024</year><volume>25</volume><fpage>179</fpage><pub-id pub-id-type="doi">10.1208/s12249-024-02893-9</pub-id><pub-id pub-id-type="pmid">39107500</pub-id></element-citation></ref><ref id="B18-pharmaceutics-17-01096"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serajuddin</surname><given-names>A.T.</given-names></name></person-group><article-title>Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs</article-title><source>J. Pharm. Sci.</source><year>1999</year><volume>88</volume><fpage>1058</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1021/js980403l</pub-id><pub-id pub-id-type="pmid">10514356</pub-id></element-citation></ref><ref id="B19-pharmaceutics-17-01096"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Asare-Addo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nokhodchi</surname><given-names>A.</given-names></name></person-group><article-title>Liqui-Tablet: The Innovative Oral Dosage Form Using the Newly Developed Liqui-Mass Technology</article-title><source>AAPS PharmSciTech</source><year>2021</year><volume>22</volume><fpage>85</fpage><pub-id pub-id-type="doi">10.1208/s12249-021-01943-w</pub-id><pub-id pub-id-type="pmid">33650023</pub-id><pub-id pub-id-type="pmcid">PMC7921041</pub-id></element-citation></ref><ref id="B20-pharmaceutics-17-01096"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nokhodchi</surname><given-names>A.</given-names></name></person-group><article-title>Producing High-Dose Liqui-Tablet (Ketoprofen 100 mg) for Enhanced Drug Release Using Novel Liqui-Mass Technology</article-title><source>J. Pharm. Innov.</source><year>2021</year><volume>17</volume><fpage>778</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1007/s12247-021-09561-6</pub-id></element-citation></ref><ref id="B21-pharmaceutics-17-01096"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cahyani</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Susanto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dewi</surname><given-names>I.R.</given-names></name><name name-style="western"><surname>Nurhikmah</surname><given-names>I.</given-names></name></person-group><article-title>Formulasi Tablet Parasetamol Dengan Kombinasi PVP dan Amilum Umbi Porang (<italic toggle="yes">Amorphopallus onchopyllus</italic>) Sebagai Bahan Pengikat Terhadap Sifat Fisik Tablet</article-title><source>J. Ilm. JOPHUS J. Pharm. UMUS</source><year>2023</year><volume>4</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.46772/jophus.v4i02.886</pub-id></element-citation></ref><ref id="B22-pharmaceutics-17-01096"><label>22.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nokhodchi</surname><given-names>A.</given-names></name></person-group><article-title>Pharmaceutical Methods and Compositions</article-title><source>International Patent Application</source><patent>No. PCT/GB2019/052065</patent><day>24</day><month>July</month><year>2019</year></element-citation></ref><ref id="B23-pharmaceutics-17-01096"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hillstrom</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jakobsson</surname><given-names>J.G.</given-names></name></person-group><article-title>Lornoxicam: Pharmacology and usefulness to treat acute postoperative and musculoskeletal pain a narrative review</article-title><source>Expert Opin. Pharmacother.</source><year>2013</year><volume>14</volume><fpage>1679</fpage><lpage>1694</lpage><pub-id pub-id-type="doi">10.1517/14656566.2013.805745</pub-id><pub-id pub-id-type="pmid">23713572</pub-id></element-citation></ref><ref id="B24-pharmaceutics-17-01096"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balfour</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Fitton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barradell</surname><given-names>L.B.</given-names></name></person-group><article-title>Lornoxicam: A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions</article-title><source>Drugs</source><year>1996</year><volume>51</volume><fpage>639</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.2165/00003495-199651040-00008</pub-id><pub-id pub-id-type="pmid">8706598</pub-id></element-citation></ref><ref id="B25-pharmaceutics-17-01096"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nousheen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rajasekaran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>M.S.</given-names></name></person-group><article-title>Solubility enhancement of lornoxicam with poloxamer 188 by solvent evaporation method</article-title><source>Int. J. Health Sci.</source><year>2022</year><volume>6</volume><fpage>8186</fpage><lpage>8195</lpage><pub-id pub-id-type="doi">10.53730/ijhs.v6nS1.6847</pub-id></element-citation></ref><ref id="B26-pharmaceutics-17-01096"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Song</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam</article-title><source>Drug Deliv.</source><year>2013</year><volume>22</volume><fpage>487</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.3109/10717544.2014.885615</pub-id><pub-id pub-id-type="pmid">24524289</pub-id></element-citation></ref><ref id="B27-pharmaceutics-17-01096"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalyanappa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Krishna</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Goli</surname><given-names>D.</given-names></name></person-group><article-title>Design and in vitro Evaluation of a Novel Sustained Release Double Layered Tablets of Lornoxicam by using semi synthetic polymers</article-title><source>Indian J. Pharm. Educ. Res.</source><year>2015</year><volume>49</volume><fpage>s31</fpage><lpage>s41</lpage><pub-id pub-id-type="doi">10.5530/ijper.49.4s.4</pub-id></element-citation></ref><ref id="B28-pharmaceutics-17-01096"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nijhawan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Santhosh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Babu</surname><given-names>P.R.S.</given-names></name><name name-style="western"><surname>Subrahmanyam</surname><given-names>C.V.S.</given-names></name></person-group><article-title>Solid state manipulation of lornoxicam for cocrystals&#8212;Physicochemical characterization</article-title><source>Drug Dev. Ind. Pharm.</source><year>2013</year><volume>40</volume><fpage>1163</fpage><lpage>1172</lpage><pub-id pub-id-type="doi">10.3109/03639045.2013.804834</pub-id><pub-id pub-id-type="pmid">23829186</pub-id></element-citation></ref><ref id="B29-pharmaceutics-17-01096"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zewail</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>ASaad</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Swellam</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Abd-Allah</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>K.HOsny</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sallah</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>E.EIssa</surname><given-names>J.</given-names></name><name name-style="western"><surname>S.MOhamed</surname><given-names>S.</given-names></name><name name-style="western"><surname>El-Dakroury</surname><given-names>W.A.</given-names></name></person-group><article-title>Design, characterization and in vivo performance of solid lipid nanoparticles (SLNs)-loaded mucoadhesive buccal tablets for efficient delivery of Lornoxicam in experimental inflammation</article-title><source>Int. J. Pharm.</source><year>2022</year><volume>624</volume><fpage>122006</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.122006</pub-id><pub-id pub-id-type="pmid">35820515</pub-id></element-citation></ref><ref id="B30-pharmaceutics-17-01096"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Usman</surname><given-names>F.</given-names></name><name name-style="western"><surname>Javed</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>S.Z.</given-names></name><name name-style="western"><surname>Ranjha</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>I.</given-names></name></person-group><article-title>Hydrophilic nanoparticles packed in oral tablets can improve the plasma profile of short half-life hydrophobic drugs</article-title><source>RSC Adv.</source><year>2016</year><volume>6</volume><fpage>94896</fpage><lpage>94904</lpage><pub-id pub-id-type="doi">10.1039/C6RA11799F</pub-id></element-citation></ref><ref id="B31-pharmaceutics-17-01096"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shokri</surname><given-names>J.</given-names></name><name name-style="western"><surname>Adibkia</surname><given-names>K.</given-names></name><name name-style="western"><surname>Javadzadeh</surname><given-names>Y.</given-names></name></person-group><article-title>Liquisolid Technology: What It Can Do for NSAIDs Delivery?</article-title><source>Colloids Surf. B Biointerfaces</source><year>2015</year><volume>136</volume><fpage>185</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">26398143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.colsurfb.2015.09.014</pub-id></element-citation></ref><ref id="B32-pharmaceutics-17-01096"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Setouhy</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Gamiel</surname><given-names>A.A.-R.</given-names></name><name name-style="western"><surname>Badawi</surname><given-names>A.A.E.-L.</given-names></name><name name-style="western"><surname>Osman</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Labib</surname><given-names>D.A.</given-names></name></person-group><article-title>Comparative study on thein vitroperformance of blister molded and conventional lornoxicam immediate release liquitablets: Accelerated stability study and anti-inflammatory and ulcerogenic effects</article-title><source>Pharm. Dev. Technol.</source><year>2016</year><volume>22</volume><fpage>256</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1080/10837450.2016.1221423</pub-id><pub-id pub-id-type="pmid">27494155</pub-id></element-citation></ref><ref id="B33-pharmaceutics-17-01096"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strickley</surname><given-names>R.G.</given-names></name></person-group><article-title>Solubilizing Excipients in Oral and Injectable Formulations</article-title><source>Pharm. Res.</source><year>2004</year><volume>21</volume><fpage>201</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1023/B:PHAM.0000016235.32639.23</pub-id><pub-id pub-id-type="pmid">15032302</pub-id></element-citation></ref><ref id="B34-pharmaceutics-17-01096"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussein</surname><given-names>A.A.</given-names></name></person-group><article-title>Preparation and Evaluation of Liquid and Solid Self-Microemulsifying Drug Delivery System of Mebendazole</article-title><source>Iraqi J. Pharm. Sci.</source><year>2017</year><volume>23</volume><fpage>89</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.31351/vol23iss1pp89-100</pub-id></element-citation></ref><ref id="B35-pharmaceutics-17-01096"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolling</surname><given-names>W.M.</given-names></name></person-group><article-title>Handbook of Pharmaceutical Excipients</article-title><source>Am. J. Pharm. Educ.</source><year>2004</year><volume>68</volume><fpage>BF1</fpage></element-citation></ref><ref id="B36-pharmaceutics-17-01096"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>C.-Y.</given-names></name><name name-style="western"><surname>Shivashekaregowda</surname><given-names>N.K.H.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Q.</given-names></name></person-group><article-title>Effects of polyvinylpyrrolidone on the crystallization of amorphous griseofulvin: Fracture and molecular mobility</article-title><source>J. Appl. Crystallogr.</source><year>2024</year><volume>57</volume><fpage>782</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1107/S1600576724003844</pub-id></element-citation></ref><ref id="B37-pharmaceutics-17-01096"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>V.</given-names></name></person-group><article-title>Tailoring of drug delivery of 5-fluorouracil to the colon via a mixed film coated unit system</article-title><source>Acta Pharm.</source><year>2011</year><volume>61</volume><fpage>343</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.2478/v10007-011-0023-5</pub-id><pub-id pub-id-type="pmid">21945913</pub-id></element-citation></ref><ref id="B38-pharmaceutics-17-01096"><label>38.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Humbert-Droz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Seidel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martani</surname><given-names>R.</given-names></name></person-group><article-title>Fast Disintegrating Oral Dosage Form</article-title><source>U.S. Patent</source><patent>6,083,531</patent><day>4</day><month>July</month><year>2000</year></element-citation></ref><ref id="B39-pharmaceutics-17-01096"><label>39.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Carstensen</surname><given-names>J.T.</given-names></name></person-group><article-title>Preformulation</article-title><source>Modern Pharmaceutics</source><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2002</year><fpage>279</fpage><lpage>313</lpage></element-citation></ref><ref id="B40-pharmaceutics-17-01096"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>J.G.</given-names></name></person-group><article-title>Interpretation of Percent Dissolved-Time Plots Derived from In Vitro Testing of Conventional Tablets and Capsules</article-title><source>J. Pharm. Sci.</source><year>1969</year><volume>58</volume><fpage>1253</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1002/jps.2600581021</pub-id><pub-id pub-id-type="pmid">5349114</pub-id></element-citation></ref><ref id="B41-pharmaceutics-17-01096"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Flanner</surname><given-names>H.H.</given-names></name></person-group><article-title>Mathematical Comparison of Dissolution Profiles</article-title><source>Pharm. Technol.</source><year>1996</year><volume>20</volume><fpage>64</fpage><lpage>74</lpage></element-citation></ref><ref id="B42-pharmaceutics-17-01096"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moutasim</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>ElMeshad</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>El-Nabarawi</surname><given-names>M.A.</given-names></name></person-group><article-title>A pharmaceutical study on lornoxicam fast disintegrating tablets: Formulation and in vitro and in vivo evaluation</article-title><source>Drug Deliv. Transl. Res.</source><year>2017</year><volume>7</volume><fpage>450</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1007/s13346-017-0367-6</pub-id><pub-id pub-id-type="pmid">28283842</pub-id></element-citation></ref><ref id="B43-pharmaceutics-17-01096"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sheinin</surname><given-names>E.B.</given-names></name></person-group><article-title>Pharmacopeial Methods and Tests</article-title><source>Specification of Drug Substances and Products</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2025</year><fpage>161</fpage><lpage>184</lpage></element-citation></ref><ref id="B44-pharmaceutics-17-01096"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wesolowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leyk</surname><given-names>E.</given-names></name></person-group><article-title>Coupled and Simultaneous Thermal Analysis Techniques in the Study of Pharmaceuticals</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>1596</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15061596</pub-id><pub-id pub-id-type="pmid">37376045</pub-id><pub-id pub-id-type="pmcid">PMC10305068</pub-id></element-citation></ref><ref id="B45-pharmaceutics-17-01096"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Majid</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maqbool</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yousaf</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>I.U.</given-names></name><name name-style="western"><surname>Mehmood</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Aleem</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arshad</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Younus</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Formulation and characterization of lornoxicam-loaded cellulosic-microsponge gel for possible applications in arthritis</article-title><source>Saudi Pharm. J.</source><year>2020</year><volume>28</volume><fpage>994</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1016/j.jsps.2020.06.021</pub-id><pub-id pub-id-type="pmid">32792844</pub-id><pub-id pub-id-type="pmcid">PMC7414098</pub-id></element-citation></ref><ref id="B46-pharmaceutics-17-01096"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zangaro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ekawa</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>A.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>G.</given-names></name><name name-style="western"><surname>Parkes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ionashiro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Caires</surname><given-names>F.</given-names></name></person-group><article-title>Lornoxicam drug&#8212;A new study of thermal degradation under oxidative and pyrolysis conditions using the thermoanalytical techniques, DRX and LC-MS/MS</article-title><source>Thermochim. Acta</source><year>2019</year><volume>680</volume><fpage>178353</fpage><pub-id pub-id-type="doi">10.1016/j.tca.2019.178353</pub-id></element-citation></ref><ref id="B47-pharmaceutics-17-01096"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suresh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nangia</surname><given-names>A.</given-names></name></person-group><article-title>Lornoxicam Salts: Crystal Structures, Conformations, and Solubility</article-title><source>Cryst. Growth Des.</source><year>2014</year><volume>14</volume><fpage>2945</fpage><lpage>2953</lpage><pub-id pub-id-type="doi">10.1021/cg500231z</pub-id></element-citation></ref><ref id="B48-pharmaceutics-17-01096"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khairnar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Harwalkar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chaudhari</surname><given-names>S.R.</given-names></name></person-group><article-title>A Review on Freeze Drying Process of Pharmaceuticals</article-title><source>Int. J. Res. Pharm. Sci.</source><year>2014</year><volume>4</volume><fpage>76</fpage><lpage>94</lpage></element-citation></ref><ref id="B49-pharmaceutics-17-01096"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumbhar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wavikar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vavia</surname><given-names>P.</given-names></name></person-group><article-title>Niosomal Gel of Lornoxicam for Topical Delivery: In vitro Assessment and Pharmacodynamic Activity</article-title><source>AAPS PharmSciTech</source><year>2013</year><volume>14</volume><fpage>1072</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1208/s12249-013-9986-5</pub-id><pub-id pub-id-type="pmid">23818079</pub-id><pub-id pub-id-type="pmcid">PMC3755149</pub-id></element-citation></ref><ref id="B50-pharmaceutics-17-01096"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colombo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Orthmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bellini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Staufenbiel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bodmeier</surname><given-names>R.</given-names></name></person-group><article-title>Influence of Drug Brittleness, Nanomilling Time, and Freeze-Drying on the Crystallinity of Poorly Water-Soluble Drugs and Its Implications for Solubility Enhancement</article-title><source>AAPS PharmSciTech</source><year>2017</year><volume>18</volume><fpage>2437</fpage><lpage>2445</lpage><pub-id pub-id-type="doi">10.1208/s12249-017-0722-4</pub-id><pub-id pub-id-type="pmid">28168626</pub-id></element-citation></ref><ref id="B51-pharmaceutics-17-01096"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurakula</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>G.K.</given-names></name></person-group><article-title>Pharmaceutical assessment of polyvinylpyrrolidone (PVP): As excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2020</year><volume>60</volume><fpage>102046</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2020.102046</pub-id><pub-id pub-id-type="pmid">32905026</pub-id><pub-id pub-id-type="pmcid">PMC7462970</pub-id></element-citation></ref><ref id="B52-pharmaceutics-17-01096"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rusdin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gazzali</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Megantara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aulifa</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Budiman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Muchtaridi</surname><given-names>M.</given-names></name></person-group><article-title>Advancing Drug Delivery Paradigms: Polyvinyl Pyrolidone (PVP)-Based Amorphous Solid Dispersion for Enhanced Physicochemical Properties and Therapeutic Efficacy</article-title><source>Polymers</source><year>2024</year><volume>16</volume><elocation-id>286</elocation-id><pub-id pub-id-type="doi">10.3390/polym16020286</pub-id><pub-id pub-id-type="pmid">38276694</pub-id><pub-id pub-id-type="pmcid">PMC10820039</pub-id></element-citation></ref><ref id="B53-pharmaceutics-17-01096"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ochi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kanda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kawachi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yuminoki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>N.</given-names></name></person-group><article-title>Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability</article-title><source>AAPS PharmSciTech</source><year>2015</year><volume>17</volume><fpage>932</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1208/s12249-015-0422-x</pub-id><pub-id pub-id-type="pmid">27435198</pub-id></element-citation></ref><ref id="B54-pharmaceutics-17-01096"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Bedi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhandari</surname><given-names>U.</given-names></name></person-group><article-title>A Review on Different Solubility Enhancement Techniques of Ticagrelor</article-title><source>Int. J. Pharm. Investig.</source><year>2022</year><volume>13</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.5530/223097131574</pub-id></element-citation></ref><ref id="B55-pharmaceutics-17-01096"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jadhav</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>A.</given-names></name></person-group><article-title>Formulation, optimization, and in vitro evaluation of polymeric nanosuspension of flurbiprofen</article-title><source>Asian J. Pharm. Clin. Res.</source><year>2019</year><volume>12</volume><fpage>183</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.22159/ajpcr.2019.v12i11.35670</pub-id></element-citation></ref><ref id="B56-pharmaceutics-17-01096"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joseph</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vedha Hari</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Devi</surname><given-names>D.R.</given-names></name></person-group><article-title>Experimental optimization of Lornoxicam liposomes for sustained topical delivery</article-title><source>Eur. J. Pharm. Sci.</source><year>2018</year><volume>112</volume><fpage>38</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2017.10.032</pub-id><pub-id pub-id-type="pmid">29111151</pub-id></element-citation></ref><ref id="B57-pharmaceutics-17-01096"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noreen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farooq</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Ghayas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bushra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yaqoob</surname><given-names>N.</given-names></name><name name-style="western"><surname>Abrar</surname><given-names>M.A.</given-names></name></person-group><article-title>Formulation and in vitro characterization of sustained release tablets of lornoxicam</article-title><source>Lat. Am. J. Pharm.</source><year>2019</year><volume>38</volume><fpage>701</fpage><lpage>711</lpage></element-citation></ref><ref id="B58-pharmaceutics-17-01096"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alhalaweh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vilinska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gavini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rassu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Velaga</surname><given-names>S.P.</given-names></name></person-group><article-title>Surface Thermodynamics of Mucoadhesive Dry Powder Formulation of Zolmitriptan</article-title><source>AAPS PharmSciTech</source><year>2011</year><volume>12</volume><fpage>1186</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1208/s12249-011-9691-1</pub-id><pub-id pub-id-type="pmid">21918918</pub-id><pub-id pub-id-type="pmcid">PMC3225526</pub-id></element-citation></ref><ref id="B59-pharmaceutics-17-01096"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name></person-group><article-title>Contact Angle Measurements: An Alternative Approach Towards Understanding the Mechanism of Increased Drug Dissolution from Ethylcellulose Tablets Containing Surfactant and Exploring the Relationship Between Their Contact Angles and Dissolution Behaviors</article-title><source>AAPS PharmSciTech</source><year>2018</year><volume>19</volume><fpage>1582</fpage><lpage>1591</lpage><pub-id pub-id-type="doi">10.1208/s12249-018-0975-6</pub-id><pub-id pub-id-type="pmid">29488194</pub-id></element-citation></ref><ref id="B60-pharmaceutics-17-01096"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanum</surname><given-names>T.I.</given-names></name><name name-style="western"><surname>Nasution</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sumaiyah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bangun</surname><given-names>H.</given-names></name></person-group><article-title>Physical stability and dissolution of ketoprofen nanosuspension formulation: Polyvinylpyrrolidone and Tween 80 as stabilizers</article-title><source>Pharmacia</source><year>2023</year><volume>70</volume><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.3897/pharmacia.70.e96593</pub-id></element-citation></ref><ref id="B61-pharmaceutics-17-01096"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bansal</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Pande</surname><given-names>V.</given-names></name></person-group><article-title>Development and Evaluation of Dual Cross-Linked Pulsatile Beads for Chronotherapy of Rheumatoid Arthritis</article-title><source>J. Pharm.</source><year>2013</year><volume>2013</volume><fpage>906178</fpage><pub-id pub-id-type="doi">10.1155/2013/906178</pub-id><pub-id pub-id-type="pmcid">PMC4595973</pub-id><pub-id pub-id-type="pmid">26556001</pub-id></element-citation></ref><ref id="B62-pharmaceutics-17-01096"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taldaev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pankov</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Terekhov</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Zhevlakova</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Selivanova</surname><given-names>I.A.</given-names></name></person-group><article-title>Modification of the Physicochemical Properties of Active Pharmaceutical Ingredients via Lyophilization</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>2607</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15112607</pub-id><pub-id pub-id-type="pmid">38004585</pub-id><pub-id pub-id-type="pmcid">PMC10674228</pub-id></element-citation></ref><ref id="B63-pharmaceutics-17-01096"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patil</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Shahi</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Udavant</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Atram</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Salunke</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Neb</surname><given-names>G.B.</given-names></name></person-group><article-title>Formulation and evaluation of quick dispersible tablet of olanzapine</article-title><source>Int. J. Pharm. Res. Dev.-Online</source><year>2009</year><volume>7</volume><fpage>001</fpage></element-citation></ref><ref id="B64-pharmaceutics-17-01096"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajebahadur</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nues</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.</given-names></name></person-group><article-title>Mechanistic Study of Solubility Enhancement of Nifedipine Using Vitamin E TPGS or Solutol HS-15</article-title><source>Drug Deliv.</source><year>2006</year><volume>13</volume><fpage>201</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1080/10717540500316094</pub-id><pub-id pub-id-type="pmid">16556572</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-01096-f001" orientation="portrait"><label>Figure 1</label><caption><p>Preparation of freeze-dried and vacuum-dried samples.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01096-g001.jpg"/></fig><fig position="float" id="pharmaceutics-17-01096-f002" orientation="portrait"><label>Figure 2</label><caption><p>(<bold>a</bold>) DSC and (<bold>b</bold>) TGA curves of API, physical mixture, vacuum-dried, and freeze-dried liquitablets.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01096-g002.jpg"/></fig><fig position="float" id="pharmaceutics-17-01096-f003" orientation="portrait"><label>Figure 3</label><caption><p>XRPD diffractograms of API, physical mixture, vacuum-dried powder, and freeze-dried powder.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01096-g003.jpg"/></fig><fig position="float" id="pharmaceutics-17-01096-f004" orientation="portrait"><label>Figure 4</label><caption><p>FT-IR spectra of API, physical mixture, freeze-dried, and vacuum-dried samples.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01096-g004.jpg"/></fig><fig position="float" id="pharmaceutics-17-01096-f005" orientation="portrait"><label>Figure 5</label><caption><p>Dissolution rate of LXM, physical mixture, freeze-dried, vacuum-dried samples, and marketed formulations in pH 1.2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01096-g005.jpg"/></fig><table-wrap position="float" id="pharmaceutics-17-01096-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01096-t001_Table 1</object-id><label>Table 1</label><caption><p>Composition of prepared physical mixture (PM), freeze-dried (FDLT), and vacuum-dried (VDLT) samples.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Composition/Tablet (% <italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Avicel<sup>&#174;</sup> PH-102</td><td align="center" valign="middle" rowspan="1" colspan="1">47.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PVP K 90</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sodium bicarbonate</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tween<sup>&#174;</sup> 80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.3</td></tr></tbody></table><table-wrap-foot><fn><p>LXM content is 8 mg in each tablet.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-01096-t002" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01096-t002_Table 2</object-id><label>Table 2</label><caption><p>Solubility of LXM in different media.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Media</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">mg/mL (<italic toggle="yes">n</italic> = 3)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Distilled water (pH 6.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0131 &#177; 0.52</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Buffer solution (pH 1.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.003 &#177; 0</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pure Tween<sup>&#174;</sup> 80</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">6.197 &#177; 0.22</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">15% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic> aqueous solution of NaHCO<sub>3</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">5.794 &#177; 0.59</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tween<sup>&#174;</sup> 80: 15% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic> aqueous solution of NaHCO<sub>3</sub> (3:1)</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">16.56 &#177; 0.94</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-01096-t003" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01096-t003_Table 3</object-id><label>Table 3</label><caption><p>Parameters of freeze-dried and vacuum-dried tablets.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Average Weight (mg)<break/>(<italic toggle="yes">n</italic> = 3)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Content (%)<break/>(<italic toggle="yes">n</italic> = 3)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dimensions<break/>(mm)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Image</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VDLT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">306 &#177; 0.94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.73 &#177; 2.676</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.802 &#215; 8.724</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-17-01096-i001.jpg"/>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDLT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">307 &#177; 0.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.45 &#177; 3.950</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.819 &#215; 8.724</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-17-01096-i002.jpg"/>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-01096-t004" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01096-t004_Table 4</object-id><label>Table 4</label><caption><p>Crystallinity percent calculated for API, PM, vacuum-dried, and freeze-dried samples.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Crystallinity (%)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">LXM</td><td align="center" valign="middle" rowspan="1" colspan="1">88.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PM</td><td align="center" valign="middle" rowspan="1" colspan="1">66.50</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VDLT</td><td align="center" valign="middle" rowspan="1" colspan="1">57.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDLT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.3</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-01096-t005" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01096-t005_Table 5</object-id><label>Table 5</label><caption><p>The polarity, the surface free energy (&#947;), and the contact angle values of API, freeze-dried, and vacuum-dried samples.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Contact Angle (&#176;)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Surface Free Energy<break/>(mN/m)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Polarity<break/>(%)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Water</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DIM</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">API</td><td align="center" valign="middle" rowspan="1" colspan="1">42.0</td><td align="center" valign="middle" rowspan="1" colspan="1">18.68</td><td align="center" valign="middle" rowspan="1" colspan="1">65.37</td><td align="center" valign="middle" rowspan="1" colspan="1">33.32</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VDLT</td><td align="center" valign="middle" rowspan="1" colspan="1">28.76</td><td align="center" valign="middle" rowspan="1" colspan="1">14.14</td><td align="center" valign="middle" rowspan="1" colspan="1">75.96</td><td align="center" valign="middle" rowspan="1" colspan="1">40.95</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDLT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.75</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-01096-t006" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01096-t006_Table 6</object-id><label>Table 6</label><caption><p>The similarity factor calculated for the dissolution rate of freeze-dried and vacuum-dried, freeze-dried, and simple and rapid-marketed products.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Similarity Factor (<italic toggle="yes">f<sub>2</sub></italic>)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">FDLT and VDLT </td><td align="center" valign="middle" rowspan="1" colspan="1">49</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FDLT and SM </td><td align="center" valign="middle" rowspan="1" colspan="1">7.45</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDLT and RM </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">79.35</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>